CYTRX CORPORATION | 1,889 Euro | -0,025 -1,31 % | |
| WKN: A1JYLF ISIN: US2328285091 Ticker-Symbol: CX5N | Frankfurt | 17.05.13 | 10:02 Uhr |
Branche BiotechnologieAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 09.05. | CYTRX CORP - 10-Q, Quaterly Report | 1 | SEC Filings | |
| 09.05. | CYTRX CORP - 8-K, Current Report | 2 | SEC Filings | |
| 08.05. | CytRx Provides Update on Clinical Programs | 2 | Benzinga.com | |
| 06.05. | CytRx Receives Recommendation from Data Safety Monitoring Committee to omplete International Phase 2b Trial with Aldoxorubicin | 2 | Benzinga.com | |
| 06.05. | CytRx Corp (CYTR) Recommended to Continue Aldoxorubicin Phase 2b to Completion | 2 | StreetInsider.com | |
| 05.03. | CytRx completes patient enrollment in tamibarotene Phase 2b study | 14 | Pharma Bus Review | |
| 23.01. | The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of CytRx Corporation in Connection with Executive Compensation | 62 | PR Newswire | |
| NEW YORK, Jan. 23, 2013 /PRNewswire/ --Levi & Korsinsky, LLP is investigating CytRx Corporation (NasdaqCM: CYTR), and its Board of Directors, in connection with the compensation provided to certain... Mehr lesen zu: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of CytRx Corporation in Connection with Executive Compensation | ||||
| 26.11. | FDA on Pace to Approve More New Drugs in 2012 Than the 30 Approved in 2011 / Five Star Equities Provides Stock Research on CytRx and ZIOPHARM Oncology | 104 | Marketwired | |
| NEW YORK, NY -- (Marketwire) -- 11/26/12 -- The Biotech Industry has skyrocketed in 2012 as an increase in the number of new drug approvals has boosted investor optimism within the industry. The iShares... Mehr lesen zu: FDA on Pace to Approve More New Drugs in 2012 Than the 30 Approved in 2011 / Five Star Equities Provides Stock Research on CytRx and ZIOPHARM Oncology | ||||
| 15.11. | CytRx's Aldoxorubicin Clinical Data Presented at Connective Tissue Oncology Society (CTOS) 7th Annual Meeting in Prague, Czech Republic | 74 | Business Wire | |
| Favorable Phase 1b/2 clinical trial results in soft tissue sarcoma
featured at third preeminent oncology conference
Company is planning to submit a special... Mehr lesen zu: CytRx's Aldoxorubicin Clinical Data Presented at Connective Tissue Oncology Society (CTOS) 7th Annual Meeting in Prague, Czech Republic | ||||
| 22.10. | Developers of Drugs for Deadly or Debilitating Diseases Could See Faster FDA Pathway / The Paragon Report Provides Stock Research on Aegerion Pharmaceuticals and CytRx | 42 | Marketwired | |
| NEW YORK, NY -- (Marketwire) -- 10/22/12 -- The Food and Drug Administration Commissioner Margaret Hamburg has told scientific advisers that the FDA is considering a faster pathway for obesity treatments... Mehr lesen zu: Developers of Drugs for Deadly or Debilitating Diseases Could See Faster FDA Pathway / The Paragon Report Provides Stock Research on Aegerion Pharmaceuticals and CytRx | ||||
| 01.10. | CytRx's Aldoxorubicin Clinical Data Presented at the ESMO 2012 Congress | 25 | Business Wire | |
| Three leading oncology conferences select aldoxorubicin Phase 1b/2
clinical trial results for presentation
CytRx
Corporation (NASDAQ: CYTR)... Mehr lesen zu: CytRx's Aldoxorubicin Clinical Data Presented at the ESMO 2012 Congress | ||||
| 07.08. | CytRx's Aldoxorubicin (INNO-206) Clinical Data to Be Featured at the ESMO 2012 Congress | 48 | Business Wire | |
| Noted sarcoma authority Dr. Sant P. Chawla to present favorable Phase
1b/2 data at prominent international conference
Abstract to be published in ESMO conference... Mehr lesen zu: CytRx's Aldoxorubicin (INNO-206) Clinical Data to Be Featured at the ESMO 2012 Congress | ||||
| 17.07. | Specialty Biotech Companies Soaring in 2012 -- Avanir Pharmaceuticals and CytRx Looking Strong / The Paragon Report Provides Stock Research on Avanir Pharmaceuticals and CytRx | 51 | Marketwired | |
| NEW YORK, NY -- (Marketwire) -- 07/17/12 -- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI)... Mehr lesen zu: Specialty Biotech Companies Soaring in 2012 -- Avanir Pharmaceuticals and CytRx Looking Strong / The Paragon Report Provides Stock Research on Avanir Pharmaceuticals and CytRx | ||||
| 02.07. | CytRx Announces Issuance of European Patent Covering INNO-206 Linker Technology | 45 | Business Wire | |
| Broad IP coverage for platform technology with blockbuster potential
extended to European Union
Aldoxorubicin selected as official generic name for doxorubicin... Mehr lesen zu: CytRx Announces Issuance of European Patent Covering INNO-206 Linker Technology | ||||
| 25.06. | Major Milestone Achieved in CytRx's Phase 2b Global Clinical Trial with Tamibarotene as a First-Line Treatment for Non-Small-Cell Lung Cancer | 39 | Business Wire | |
| Independent Data Safety Monitoring Board recommends continuation of
Phase 2b trial
Trial data expected in 2013
CytRx
Corporation... Mehr lesen zu: Major Milestone Achieved in CytRx's Phase 2b Global Clinical Trial with Tamibarotene as a First-Line Treatment for Non-Small-Cell Lung Cancer | ||||
| 15.06. | Mergers and Acquisitions Activity Expected to Pick Up as a Result of Big Pharmaceuticals Expiring Patents / Five Star Equities Provides Stock Research on BioSante Pharmaceuticals and CytRx | 73 | Marketwired | |
| NEW YORK, NY -- (Marketwire) -- 06/15/12 -- Despite the recent economic turmoil in Europe, the Biotech Industry has been home to some of the strongest performers in the market in 2012. The SPDR S&P... Mehr lesen zu: Mergers and Acquisitions Activity Expected to Pick Up as a Result of Big Pharmaceuticals Expiring Patents / Five Star Equities Provides Stock Research on BioSante Pharmaceuticals and CytRx | ||||
| 13.06. | CytRx Set to Join the Russell Microcap Index | 52 | Business Wire | |
| CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing
in oncology, today announced that it is expected to join the Russell
Microcap® Index... Mehr lesen zu: CytRx Set to Join the Russell Microcap Index | ||||
| 04.06. | CytRx to Hold Conference Call Today at 10:00 a.m. Eastern Time to Discuss Favorable Results from INNO-206 Clinical Trial in Soft Tissue Sarcoma | 37 | Business Wire | |
| 77% of evaluable advanced soft tissue sarcoma patients administered
INNO-206 at the maximum tolerated dose showed clinical benefit of more
than four months following treatment
Company... Mehr lesen zu: CytRx to Hold Conference Call Today at 10:00 a.m. Eastern Time to Discuss Favorable Results from INNO-206 Clinical Trial in Soft Tissue Sarcoma | ||||
| 03.06. | CytRx Announces Favorable Results from Phase 1b/2 Clinical Trial with INNO-206 | 120 | Business Wire | |
| 77% of evaluable advanced soft tissue sarcoma patients administered
INNO-206 at the maximum tolerated dose showed clinical benefit of more
than four months following treatment
Company... Mehr lesen zu: CytRx Announces Favorable Results from Phase 1b/2 Clinical Trial with INNO-206 | ||||
| 01.06. | CytRx Regains NASDAQ Compliance | 37 | Business Wire | |
| CytRx
Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing
in oncology, today announced that it received written notification on
May 31, 2012 from... Mehr lesen zu: CytRx Regains NASDAQ Compliance | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| CELL THERAPEUTICS | 0,877 | -1,13 % | Cell Therapeutics to Present at Upcoming Investor Conferences |
| GENEREX BIOTECHNOLOGY | 0,02 | 0 % | Generex Comments on Results of Stockholders' Meeting |
| MOLOGEN | 14,15 | +2,50 % | MOLOGEN AG weitet Forschungs- und Entwicklungsaktivitäten im ersten Quartal aus |
| EVOTEC | 2,818 | +0,07 % | Evotec: Kurs der Aktie hat weiteres Potenzial |
| PAION | 0,686 | -1,30 % | Paion: Kaufempfehlung wird erneuert |
